A team including the scientist who first harnessed the revolutionary CRISPR-Cas9 system for mammalian genome editing has now identified a different CRISPR system with the potential for even simpler and more precise genome engineering. In a study published today in Cell, Feng Zhang and his colleagues at the Broad Institute of MIT and Harvard and the McGovern Institute for Brain Research at MIT, with co-authors Eugene Koonin at the National Institutes of Health, Aviv Regev of the Broad Institute and the MIT Department of Biology, and John van der Oost at Wageningen University, describe the unexpected biological features of this new system and demonstrate that it can be engineered to edit the genomes of human cells.

 

"This has dramatic potential to advance genetic¹ engineering," said Eric Lander, Director of the Broad Institute and one of the principal leaders of the human genome project. "The paper not only reveals the function of a previously² uncharacterized CRISPR system, but also shows that Cpf1 can be harnessed for human genome editing and has remarkable³ and powerful features. The Cpf1 system represents a new generation of genome editing technology."

 

CRISPR sequences were first described in 1987 and their natural biological function was initially⁴ described in 2010 and 2011. The application of the CRISPR-Cas9 system for mammalian genome editing was first reported in 2013, by Zhang and separately by George Church at Harvard. 

 

In the new study, Zhang and his collaborators searched through hundreds of CRISPR systems in different types of bacteria, searching for enzymes⁵ with useful properties that could be engineered for use in human cells. Two promising⁶ candidates were the Cpf1 enzymes from bacterial⁷ species Acidaminococcus and Lachnospiraceae, which Zhang and his colleagues then showed can target genomic loci in human cells.

 

"We were thrilled to discover completely different CRISPR enzymes that can be harnessed for advancing research and human health," Zhang said.

点击收听单词发音